December 2020 QQ: Emicixumab Responses

Here are the responses to our December, 2020 Quick Question: “What therapeutic does your center use for hemophilia A patients with inhibitors who bleed during emicizumab therapy?” There were only 6 voters

1. Activated prothrombin complex concentrate [APCC]: 0
2. Recombinant activated factor VII [rFVIIa]: 4
3. Low-dose factor VIII: 1
4. High-dose factor VIII: 0
5. None, we see no bleeds: 1

Our new “ReCaptcha” function, designed to trap spam, slowed our December voting, however it appears that recombinant activated factor VII [NovoSeven, rFVIIa] is the treatment of choice. Thank you for your votes.